300147 ST香雪制药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-24.934-57.629-18.384-20.184-21.331
总资产报酬率 ROA (%)-3.139-10.882-4.597-5.295-5.941
投入资产回报率 ROIC (%)-6.916-20.929-7.820-8.881-9.384

边际利润分析
销售毛利率 (%)28.52624.36534.34824.86926.277
营业利润率 (%)-22.517-42.209-14.470-21.222-19.366
息税前利润/营业总收入 (%)-9.881-32.876-6.414-13.687-14.125
净利润/营业总收入 (%)-26.609-46.336-17.473-23.074-21.774

收益指标分析
经营活动净收益/利润总额(%)80.14548.46139.38575.91831.632
价值变动净收益/利润总额(%)-0.4960.63712.318-9.244-7.911
营业外收支净额/利润总额(%)15.0936.83414.4589.3237.563

偿债能力分析
流动比率 (X)0.2700.2980.3530.3240.486
速动比率 (X)0.2230.2340.2740.2340.366
资产负债率 (%)83.50680.81172.06568.52665.794
带息债务/全部投入资本 (%)71.84266.82953.75551.03254.570
股东权益/带息债务 (%)35.05445.06876.14986.17079.092
股东权益/负债合计 (%)13.28017.40932.25438.95340.440
利息保障倍数 (X)-0.594-2.645-0.611-1.409-2.070

营运能力分析
应收账款周转天数 (天)188.450146.725102.156139.642129.415
存货周转天数 (天)95.15996.314104.740134.579131.612